ORTIN GLOBAL LIMITEDORTINGLOBECorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2012 3 quarters of data

₹14.34

MCap ₹12 Cr

ORTIN GLOBAL LIMITED — Stock analysis & AI research ORTIN GLOBAL LIMITED — Seasonality — best & worst months ORTIN GLOBAL LIMITED — Technical setup — score, trend, support & resistance ORTIN GLOBAL LIMITED — Live exchange announcements

🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹16 Cr

Sales · Jun 2012

-19.6% YoY

₹2 Cr

Operating Profit · Jun 2012

-22.4% YoY

13.1%

OPM % · Jun 2012

-3.0% YoY

₹0 Cr

Net Profit · Jun 2012

-63.3% YoY

₹0.26

EPS · Jun 2012

-92.0% YoY

📝 ORTIN GLOBAL LIMITED — results explained

Quarter ended June 2012 (Q1 FY13)

ORTIN GLOBAL LIMITED reported revenue of ₹16 crore for the quarter ended June 2012 (Q1 FY13), down 19.6% from ₹20 crore in the same quarter last year, and down 19.4% sequentially over the March 2012 quarter.

Net profit fell 63.3% year-on-year to ₹0 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹0.26.

Operating profit stood at ₹2 crore — an operating margin (OPM) of 13.1%, compared with 13.5% in the year-ago quarter.

Valuation snapshot

At the current price of ₹14.34, ORTINGLOBE has a market capitalisation of ₹12 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 1.24%, foreign institutional investors (FIIs) 0.67%, public shareholders 98.09% of ORTIN GLOBAL LIMITED.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹12 Cr

Current Price ?

₹14.3

P/E ?

N/A

Industry P/E ?

37.20

P/B ?

9.40

P/S ?

N/A

P/FCF ?

-22.42

Enterprise Value ?

₹13 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

-32.1%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹16 Cr

PAT — latest qtr ?

₹0 Cr

YoY qtr sales growth ?

-19.6%

YoY qtr profit growth ?

-63.3%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹1 Cr

Debt to Equity ?

0.81

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

1.24%

Change in promoter holding ?

0.01%

Pledged percentage ?

N/A

Market

Return 3 months ?

-7.5%

Return 6 months ?

-4.2%

🗓️ Quarterly results (3 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Jun 2011	Mar 2012	Jun 2012	YoY %	QoQ %
Sales	20	20	16	-19.6%	-19.4%
Operating Profit	3	-1	2	-22.4%	+308.0%
Other Income	0	0	0	+200.0%	-84.2%
Interest	1	1	1	+103.6%	+14.3%
Depreciation	0	0	0	-2.9%	-15.4%
Profit Before Tax	2	-2	1	-63.3%	+130.3%
Net Profit	1	-2	0	-63.3%	+122.9%
EPS	3.24	-1.14	0.26	-92.0%	+122.8%
OPM %	13.5%	-5.1%	13.1%	-3.0%	+356.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	8.13	8.13	8.13	8.13	+0.0%
Reserves	2.73	-5.31	-6.15	-6.89	-12.0%
Borrowings	6.45	1.80	0.25	1.01	+304.0%
Other Liabilities	3.89	2.05	1.55	2.40	+54.8%
Total Liabilities	21.20	6.67	3.78	4.65	+23.0%
Fixed Assets	13.96	0.01	0.00	0.01	—
CWIP	0.43	0.00	0.00	0.00	—
Investments	0.00	0.00	0.00	0.00	—
Other Assets	6.81	6.66	3.78	4.64	+22.8%
Total Assets	21.20	6.67	3.78	4.65	+23.0%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	-0.25	-4.79	-0.41	-0.56	-36.6%
Cash from Investing Activity	0.01	12.00	0.00	0.04	—
Cash from Financing Activity	0.90	-3.49	0.33	0.75	+127.3%
Net Cash Flow	0.66	3.72	-0.09	0.23	+355.6%
Free Cash Flow	-0.24	7.21	-0.41	-0.52	-26.8%
CFO/OP	-47%	80%	46%	78%	+69.6%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	208.05	321.42	279.12	178.05	-36.2%
Inventory Days	279.94	4.92	34.76	0.00	-100.0%
Days Payable	166.89	7.87	69.52	—	—
Cash Conversion Cycle	321.10	318.47	244.36	178.05	-27.1%
Working Capital Days	-43.19	357.74	1,524.41	730.00	-52.1%
ROCE %	1.80%	-40.58%	-25.11%	-32.14%	-28.0%

👥 Shareholding (latest 6 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026	% Chg
Promoters	1.23%	1.23%	1.23%	1.23%	1.23%	1.24%	+0.8%
FIIs	6.53%	1.68%	1.68%	1.68%	1.80%	0.67%	-62.8%
Public	92.24%	97.08%	97.09%	97.10%	96.96%	98.09%	+1.2%
No. of Shareholders	12,034	12,060	11,834	11,452	11,383	11,151	-2.0%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	ORTINGLOBE ORTIN GLOBAL	₹15.20	12	—	0	-1	-266.2%	-267.2%	5.3%	11.9%	-80.0%	-87.7%

❓ Frequently asked questions

What was ORTIN GLOBAL LIMITED's revenue in Q1 FY13?

What was ORTIN GLOBAL LIMITED's net profit in Q1 FY13?